EC Dental Science

Literature Review Volume 22 Issue 3 - 2023

Human Herpes Varicella Zoster: An Appraisal, Pathogenesis and Therapy

Louis ZG Touyz1*, Sarah JJ Touyz2 and Leonardo M Nassani3,4

1Faculty of Dental Medicine and Oral Health Sciences, University of McGill, Montreal, PQ, Canada
2Internal Medicine, Salford Royal NHS Foundation Trust Hospital, Salford UK
3Assistant Professor, Division of Restorative and Prosthetic Dentistry, The Ohio State University College of Dentistry, Columbus, OH, USA
4Emeritus Director and Professor, Periodontics, Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, PQ, Canada

*Corresponding Author:Louis ZG Touyz, Faculty of Dental Medicine and Oral Health Sciences, University of McGill, Montreal, PQ, Canada.
Received: February 18, 2023; Published: February 27, 2023



Objective: This appraisal describes the pathogenesis and presentations of primary and secondary Human Herpes Viruses particularly focusing on the Shingles Human Herpes Virus, Varicella Zoster (HHVZ).

Design: Pertinent literature on management and treatment of Human Herpes Varicella Zoster Viruses were reviewed.

Results: Primary exposure HHVZ infection manifests as Chicken-pox mainly in children. Subsequently HHVZ settles into sensory ganglions, where immunity restrains its’ activity. As age reduces immunity recrudescence of HHVZ is stimulated, and infected persons manifest crops of painful vesicles. A reliable prophylactic vaccine against HHVZ exists and antiviral medications effectively moderates symptoms and manifestations.

Conclusion: Recrudescence of HHSVZ remains obscure but successful prevention resides in vaccines. Common stigmata locations are indicated and anti-virals for HHSVZ are tabled.

Keywords: Chickenpox; Herpes; Singles; Varicella; Virus; Zoster

  1. Norkin LC. “Herpesviruses in Virology: Molecular biology and pathogenesis”. Washington, DC: ASM Press. Ch 18 (2010): 471-520.
  2. Whitley RJ and Roizman B. “Herpes simplex virus infections”. The Lancet9267 (2001): 1513-1518.
  3. Creed R and Satyaprakash AP. “Varicella zoster vaccines”. Dermatologic Therapy2 (2009): 143-149.
  4. Gray WL. “Simian varicella: a model for human varicella-zoster virus infections”. Reviews in Medical Virology6 (2004): 363-381.
  5. Arvin AM., et al. “Varicella-zoster virus T cell tropism and the pathogenesis of skin infection”. Current Topics in Microbiology and Immunology 342 (2010): 189-209.
  6. Corey L., et al. “Genital herpes simplex virus infections: clinical manifestations, course, and complications”. Annals of Internal Medicine6 (1983): 958-972.
  7. Saleh D., et al. Herpes Simplex Type 1 (2021).
  8. Davies N., et al. “Herpes simplex virus type 2 and recurrent meningitis”. The Lancet9433 (2004): 501-502.
  9. Corey L. “First-episode, recurrent, and asymptomatic herpes simplex infections”. Journal of the American Academy of Dermatology1-2 (1988): 169-172.
  10. Gershon A., et al. “Varicella zoster virus infection”. Nature Reviews Disease Primers 1 (2015): 15016.
  11. Arvin A., et al. “Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis”. Cambridge: Cambridge University Press (2007).
  12. Weinberg JM. “Herpes zoster: Epidemiology, natural history, and common complications”. Journal of the American Academy of Dermatology6 (2007): S148-S149.
  13. Kawai K., et al. “Systematic review of incidence and complications of herpes zoster: towards a global perspective”. BMJ Open 4 (2014): e004833.
  14. Kamma J., et al. “Herpes viruses and periodontopathic bacteria in early-onset periodontitis”. Journal of clinical Periodontology9 (2001): 879-885.
  15. Contreras A and Slots J. “Herpesviruses in periodontal diseases”. Journal of Periodontal Research 35 (2000): 3-16.
  16. Slots J. “Oral viral infections of adults”. Periodontology 2000 49 (2009): 60-86.
  17. Slots J. “Human viruses in periodontitis”. Periodontology 2000 53 (2010): 89-110.
  18. Straface G., et al. “Herpes Simplex Virus Infection in Pregnancy”. Infectious Diseases Obstetrics Gynecology (2012).
  19. Anzivino E., et al. “Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention”. Virology Journal6-40 (2009).
  20. Anderson TC., et al. “Use of recombinant Zoster Vaccine in Immunosuppressed adults. Aged≥19 years: Recommendations of the Advisory Committee on Immunization Practices- United States, 2022”. Morbidity and Mortality Weekly Report80 (2022): 80-84.
  21. Food and Drug Administration. Shingrix [package insert], revised: 07/2021. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration (2021).
  22. Singh G., et al. “Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia”. The Korean Journal of Pain3 (2020): 201-207.
  23. Kroger A., et al. “General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP)”. Atlanta, GA: US Department of Health and Human Services, CDC (2022).
  24. McGirr A., et al. “The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis”. Vaccine 37 (2019): 2896-2909.
  25. Vink P., et al. “Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial”. Clinical Infectious Diseases 0 (2020): 18190.
  26. Whitley R., et al. “Pathogenesis and disease”. In: Human Herpes viruses: Biology, Therapy, and Immuno-prophylaxis”. Cambridge University Press, Cambridge (2007).
  27. (PDF) Herpes Viruses: An Appraisal, Clinical Reports and Insights (2021).
  28. Stevens DA and Merigan TC. “Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial”. International Archives of Internal Medicine1 (1980): 52-54.
  29. Kausmally L., et al. “Neutralizing human antibodies to varicella-zoster virus (VZV) derived from a VZV patient recombinant antibody library”. Journal of General Virology12 (2004): 3493-3500.
  30. Mitka M. "FDA approves shingles vaccine: herpes zoster vaccine targets older adults". The Journal of the American Medical Association2 (2006): 157-158.
  31. Pan CX., et al. “Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review". Therapeutic Advances in Vaccines and Immunotherapy (2022): 10.
  32. Han Da Hee. "ACIP: New Vaccine Recommendations for Shingles Prevention". MPR (2017).
  33. Gershon MD and Gershon AA. “VZV infection of keratinocytes: production of cell-free infectious virions in vivo”. Current Topics in Microbiology and Immunology 342 (2010): 173-188.
  34. Pedersen C., et al. “Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant”. Journal of Adolescent Health 40 (2007): 564-571.
  35. Campbell A., et al. “Literature review on one and two-dose varicella vaccination”. Canada Communicable Disease Report10 (2010): 1-24.
  36. Kimberlin DW and Whitley RJ. “Antiviral therapy of HSV-1 and -2”. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press 64 (2007).
  37. Arvin AM. “Varicella-zoster virus (VZV) ASM Journals”. Clinical Microbiology Reviews3 (2021).
  38. Marrack P., et al. “Towards an understanding of the adjuvant action of aluminium”. Nature Reviews Immunology 9 (2009): 287-293.
  39. Wilkins AL., et al. “AS03- and MF59-adjuvanted influenza vaccines in children”. Frontiers in Immunology 8 (2017): 1760.
  40. Kaslow DC and Biernaux S. “RTS,S: toward a first landmark on the Malaria Vaccine Technology Roadmap”. Vaccine 33 (2015): 7425-7432.
  41. Bulakbas IN and Kocaoglu M. “Central Nervous System Infections of Herpesvirus Family”. Neuroimaging Clinics of North America 1 (2008): 53-84.
  42. Touyz L.Z.G. (2023) Periodontitis: A Dual Infection. Current Opinion. CO 3 (1). 238-248.
  43. Nassani L.M., Fernandes J.C.H., Fernandes G.V.O., Touyz L.Z.G. (2023). Herpes gladiatorum in sports: an appraisal for health care workers and team dentist. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. DOI: 10.1016/j.ajoms.2023.02.005

Louis ZG Touyz., et al. “Human Herpes Varicella Zoster: An Appraisal, Pathogenesis and Therapy”.”. EC Dental Science 22.3 (2023): 118-125.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.org

Colored Stripes